Scientists launch national study to track immune weakness linked to severe COVID

NCT ID NCT06762002

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study follows 500 adults in France who have either a genetic defect or autoantibodies that weaken their type I interferon immune response. Researchers will collect blood samples and health data over 1 to 4 years to track infections, autoimmune diseases, and cancers. The goal is to better understand and manage these immune deficiencies, but no new treatments are being tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could improve how doctors monitor and manage patients with type I interferon deficiencies, potentially reducing severe infections.
What could go wrong
This is an observational study, not a treatment trial. It will not directly cure or treat any disease, and results may take years to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cic Bichat

    RECRUITING

    Paris, France

  • Cic Creteil

    RECRUITING

    Paris, France

  • Cic La Salpetriere

    RECRUITING

    Paris, France

  • Cic Lille

    RECRUITING

    Lille, France

  • Cic Montpellier

    RECRUITING

    Montpellier, France

  • Cic Necker

    RECRUITING

    Paris, France

  • Cic St Louis

    RECRUITING

    Paris, France

  • Cic Tours

    RECRUITING

    Tours, France

  • LYON HCL

    RECRUITING

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.